Asst. Prof. ERTUĞRUL ÇAĞRI BÖLEK

Publication Network

Articles 70

1. Ophthalmic involvement in VEXAS syndrome and its influence on mortality: insights from the international AIDA network registry

Sota J., Hinojosa-Azaola A., Martin-Nares E., Sfriso P., Bindoli S., Hissaria P., et al.

FRONTIERS IN IMMUNOLOGY , vol.17, 2026 (SCI-Expanded, Scopus)

2. Building bridges for early-career rheumatologists in Türkiye: insights from the Turkish Society for Rheumatology—young rheumatologists

BÖLEK E. Ç., Ayan G., BİLGİN E., Ilgen U., Oztas M., Kabasakal Y., et al.

Rheumatology , vol.65, no.2, 2026 (SCI-Expanded, Scopus)

3. Lipoid proteinosis mimicking Sjögren’s syndrome: a diagnostic challenge in rheumatology practice

Baltaci M. A., Taşdelen E., Toptas G., Pamukcu M., Kurtulus Ozturk E., Ozmen O., et al.

Rheumatology , vol.65, no.2, 2026 (SCI-Expanded, Scopus)

4. Assessment of interstitial lung disease in systemic sclerosis using oscillometric methods: a novel approach to respiratory assessment

Vasi İ., Karaduman İ., Alacaoğlu Ş., Duygulu S., Kardaş R. C., Yıldırım D., et al.

RHEUMATOLOGY , vol.65, no.1, 2026 (SCI-Expanded, Scopus) Sustainable Development

5. Venous Thromboembolism May Be Increased in the Early Phases of ANCA-Associated Vasculitis and Could Be Associated With a High Body Mass Index: TR-VaS Experience

Kocaayan H., Ediboglu E. D., Yıldırım T. D., Ulusoy B. O., Ogut T. S., Firlatan B., et al.

International journal of rheumatic diseases , vol.28, no.12, 2025 (SCI-Expanded, Scopus)

6. Genetic susceptibility and validation of angiographic patterns in Takayasu arteritis

Casares-Marfil D., Gribbons K. B., Saruhan-Direskeneli G., Kaymaz-Tahra S., Quinn K. A., Alibaz-Oner F., et al.

Journal of Autoimmunity , vol.157, 2025 (SCI-Expanded, Scopus)

7. Turkish Society for Rheumatology (Turkish Takayasu Arteritis Study Group) recommendations for the diagnosis, follow-up and the treatment of Takayasu's arteritis

ALİBAZ ÖNER F., Kaymaz-Tahra S., Ince B., BÖLEK E. Ç., Yüce Inel T., Öz H. E., et al.

Clinical and experimental rheumatology , vol.43, no.11, pp.1928-1944, 2025 (SCI-Expanded, Scopus)

8. Use of JAK inhibitors in patients with refractory Takayasu arteritis: A worldwide retrospective study

ALİBAZ F., ÇAKIR İ. Y., Tomelleri A., Avcu A., Quinn K., Misra D. P., et al.

ARTHRITIS & RHEUMATOLOGY , vol.77, pp.3169-3171, 2025 (SCI-Expanded, Scopus)

9. Refractory Nodular Scleritis as a Presenting Sign of Colorectal Cancer

Duran R., Kıran Y., Özdemir Yalçınsoy K., Bölek E. Ç., Erden A.

OCULAR IMMUNOLOGY AND INFLAMMATION , vol.33, no.7, pp.1479-1482, 2025 (SCI-Expanded, Scopus) Sustainable Development

10. Educational and skill development needs of early-career rheumatologists in Türkiye Türkiye’de çalışmakta olan kariyerinin başındaki romatologların eğitim ve beceri geliştirme ihtiyaçları

Öztaş M., Ayan G., BİLGİN E., BÖLEK E. Ç., İlgen U.

Journal of Turkish Society For Rheumatology , vol.17, no.2, pp.102-106, 2025 (Scopus, TRDizin)

11. Comment on: Fibroblast activation protein inhibitor-positron emission tomography in aortitis: fibroblast pathology in active inflammation and remission

Bolek E. Ç., Karadeniz H., TUFAN A.

RHEUMATOLOGY , vol.64, no.6, pp.4087-4088, 2025 (SCI-Expanded, Scopus)

12. Is Myopenia or Myosteatosis Clinically Relevant in Systemic Sclerosis? Skeletal Muscle Assessment Using Computed Tomography

Kılıç A. C., Vasi İ., Kılıç H. K., Erden A., Gündoğdu O., Kardaş R. C., et al.

ACADEMIC RADIOLOGY , vol.32, no.6, pp.3574-3584, 2025 (SCI-Expanded, Scopus) Sustainable Development

13. DOES CRANIAL GIANT CELL ARTERITIS (GCA) AFFECT BRANCHES OF BOTH EXTERNAL AND INTERNAL CAROTID ARTERIES ATRANSORBITAL DOPPLER ULTRASOUND AND OPTICAL COHERENCE TOMOGRAPHY STUDY

KARADAĞ Ö., Uzun G. S., ESEN Ü., Sadigh S. L., Tahillioglu Y., Tan A. A., et al.

ANNALS OF THE RHEUMATIC DISEASES , vol.84, pp.429-430, 2025 (SCI-Expanded, Scopus) Sustainable Development

14. MUSCLE MRI IN POLYARTERITIS NODOSA: CONSISTENT FINDINGS IN 6 PATIENTS

KARADAĞ Ö., Yazgan B. F., Ayan G., BÖLEK E. Ç., KALYONCU U., YILDIZ A. N., et al.

ANNALS OF THE RHEUMATIC DISEASES , vol.84, 2025 (SCI-Expanded, Scopus)

15. WHAT HAS THE FDA'S BLACK BOX WARNINGS FOR JAKi CHANGED IN REAL LIFE HUR-BIO REAL-LIFE EXPERIENCE

Bulat B., Ekici M., Yazgan B. F., Bayram G. S. K., Unaldi E., Ayan G., et al.

ANNALS OF THE RHEUMATIC DISEASES , vol.84, 2025 (SCI-Expanded, Scopus)

16. BEHCET'S DISEASE BEYOND THE CRITERIA: INSIGHTS FROM ATERTIARY CENTER IN TURKEY

Yazgan B. F., Mavi E. A. S., Bayram G. S. K., Bulat B., Ekici M., Unaldi E., et al.

ANNALS OF THE RHEUMATIC DISEASES , vol.84, pp.1577, 2025 (SCI-Expanded, Scopus)

17. Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer

Sebbag E., Molina-Collada J., Ndoye R., Aletaha D., Askling J., Gente K., et al.

ANNALS OF THE RHEUMATIC DISEASES , vol.84, pp.643-652, 2025 (SCI-Expanded, Scopus) Sustainable Development

18. 2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer

Sebbag E., Lauper K., Molina-Collada J., Aletaha D., Askling J., Gente K., et al.

ANNALS OF THE RHEUMATIC DISEASES , vol.84, pp.388-397, 2025 (SCI-Expanded, Scopus) Sustainable Development

19. Behçet's disease beyond the criteria: insights from a tertiary centre in Turkey.

Firlatan Yazgan B., Sahin Mavi E. A., Kart Bayram G. S., Bulat B., Ekici M., Unaldi E., et al.

Clinical and experimental rheumatology , vol.43, pp.1782-1788, 2025 (SCI-Expanded, Scopus)

20. Clinical Characteristics and Outcomes of Polyarteritis Nodosa: An International Study.

Karadag O., Bolek E. Ç., Ayan G., Mohammad A. J., Grayson P. C., Pagnoux C., et al.

Arthritis & rheumatology (Hoboken, N.J.) , vol.76, no.7, pp.1120-1129, 2024 (SCI-Expanded, Scopus)

21. Unveiling cancer risk in ANCA-associated vasculitis: result from the Turkish Vasculitis Study Group (TRVaS).

Bilgin E., Demirci Yıldırım T., Özdemir Ulusoy B., Öğüt T. S., Karabacak M., Sadioğlu Çağdaş Ö., et al.

Internal and emergency medicine , vol.19, no.4, pp.1025-1034, 2024 (SCI-Expanded, Scopus)

22. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update

Dejaco C., Ramiro S., Bond M., Bosch P., Ponte C., Mackie S. L., et al.

ANNALS OF THE RHEUMATIC DISEASES , vol.83, no.6, pp.741-751, 2024 (SCI-Expanded, Scopus) Sustainable Development

23. Development of the Takayasu Arteritis Integrated Disease Activity Index

Marvisi C., BÖLEK E. Ç., Ahlman M. A., Alessi H., Redmond C., Muratore F., et al.

ARTHRITIS CARE & RESEARCH , vol.76, no.4, pp.531-540, 2024 (SCI-Expanded, Scopus) Sustainable Development

24. Factors that predict development of chronic kidney disease in patients with rheumatoid arthritis receiving biologic DMARDs and mortality rates

Uzun G. S., Taghiyeva A., YALÇIN ÇAKIR F., Moral K., Yardimci G. K., BÖLEK E. Ç., et al.

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES , vol.27, no.1, 2024 (SCI-Expanded, Scopus) Sustainable Development

25. A close look at the nutritional status and mediterranean diet adherence in patients with Behcet's syndrome

ERSOY N., BÖLEK E. Ç., Farisogullari B., Cinar N., Garipoglu G., Colak S., et al.

MEDITERRANEAN JOURNAL OF NUTRITION AND METABOLISM , vol.17, no.1, pp.43-52, 2024 (ESCI, Scopus) Sustainable Development

26. IgG4-related pachymeningitis-Long term follow up and outcome of six patients

Yardimci G. K., Arslan D., Babaoglu B., BÖLEK E. Ç., KILIÇ L., AYHAN E. A., et al.

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES , vol.26, no.9, pp.1853-1860, 2023 (SCI-Expanded, Scopus) Sustainable Development

27. Comparison of demographic, clinic and radiological features of patients with axial spondyloarthritis accompanying familial Mediterranean fever to patients with each condition alone

Kiraci M., BİLGİN E., Duran E., Farisogullari B., BÖLEK E. Ç., Yardimci G. K., et al.

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY , vol.52, no.5, pp.530-538, 2023 (SCI-Expanded, Scopus) Sustainable Development

28. High 30-day readmission rates in hospitalized patients with heart failure: Strengthening the need for a multidisciplinary and integrated approach

Bolek H., cetik s., CEYLAN F., Bolek E. C., Uyaroğlu O. A., Tanriover M. D.

Acta Medica , vol.54, no.2, pp.116-126, 2023 (TRDizin)

29. Fertility, early menopause and pregnancy outcomes of patients with Takayasu?s arteritis

Taghiyeva A., KILIÇ L., ÇAĞAN M., BÖLEK E. Ç., Yardimci G. K., Ozyuncu O., et al.

EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY , vol.283, pp.1-5, 2023 (SCI-Expanded, Scopus) Sustainable Development

30. Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis

Armagan B., KILIÇ L., Farisogullari B., Yardimci G. K., BİLGİN E., BÖLEK E. Ç., et al.

RHEUMATOLOGY INTERNATIONAL , vol.43, no.1, pp.147-156, 2023 (SCI-Expanded, Scopus) Sustainable Development

31. Investigation of anterior segment structures of the eye in Behcet's disease using in vivo confocal microscopy

DİKMETAŞ SANDIKÇI Ö., Aygun O., BÖLEK E. Ç., KOCABEYOĞLU S., KARADAĞ Ö., KARAKAYA KARABULUT J., et al.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY , vol.260, no.12, pp.3897-3902, 2022 (SCI-Expanded, Scopus) Sustainable Development

32. Use of ¹⁸F-fluorodeoxyglucose positron emission tomography to standardize clinical trial recruitment in Takayasu's arteritis

Quinn K. A., Alessi H., Ponte C., Rose E., Ahlman M. A., Redmond C., et al.

RHEUMATOLOGY , vol.61, no.10, pp.4047-4055, 2022 (SCI-Expanded, Scopus) Sustainable Development

33. Somatic mutations in rheumatological diseases: VEXAS syndrome and beyond

Sikora K. A., Wells K., BÖLEK E. Ç., Jones A., Grayson P. C.

RHEUMATOLOGY , vol.61, no.8, pp.3149-3160, 2022 (SCI-Expanded, Scopus) Sustainable Development

34. Isolated spinal cord granulomatous angiitis: a case report and review of the literature

AYVACIOĞLU ÇAĞAN C., TEMUÇİN Ç. M., Arslan D., GÖÇMEN R., BÖLEK E. Ç., Söylemezoğlu F., et al.

Journal of Neurology , vol.269, no.6, pp.3175-3179, 2022 (SCI-Expanded, Scopus)

35. Anxiety levels before biologic initiation and changes with treatment in patients with psoriatic arthritis: HUR-BIO biologic registry results

Ayan G., Farisogullari B., BİLGİN E., BÖLEK E. Ç., KubraYardimci G., Duran E., et al.

CLINICAL RHEUMATOLOGY , vol.41, no.5, pp.1439-1446, 2022 (SCI-Expanded, Scopus) Sustainable Development

36. Comprehensive assessment and outcomes of patients with chronic periaortitis

Yardimci G., Düzgün S. A., Farisogullari B., Bolek E. Ç., ELDEM F. G., Erden A., et al.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , vol.40, no.4, pp.801-810, 2022 (SCI-Expanded, Scopus) Sustainable Development

37. The clinical features and treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in Turkey: one or two distinct diseases?

Duran E., Bostan O. C., BİLGİN E., KAYA S. B., BÖLEK E. Ç., ÖZER S., et al.

INTERNAL AND EMERGENCY MEDICINE , vol.17, no.3, pp.743-751, 2022 (SCI-Expanded, Scopus) Sustainable Development

38. A prospective observational cohort study and systematic review of 40 patients with mouth and genital ulcers with inflamed cartilage (MAGIC) syndrome

Luo Y., BÖLEK E. Ç., Quinn K. A., Wells K., Rose E., Sikora K., et al.

Seminars in Arthritis and Rheumatism , vol.52, 2022 (SCI-Expanded, Scopus)

39. Is the impact of biologic agents in enteropathic spondylitis different from other spondylitis? Real life data from the HUR-BIO Registry

Farisogullari B., Yardimci G. K., Sari A., BİLGİN E., BÖLEK E. Ç., Duran E., et al.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , vol.40, no.1, pp.112-119, 2022 (SCI-Expanded, Scopus) Sustainable Development

40. Pleuroparenchymal fibroelastosis in systemic sclerosis-associated interstitial lung disease

Sari A., Onder O., Armagan B., BÖLEK E. Ç., Farisogullari B., BİLGİN E., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , vol.52, no.1, pp.83-88, 2022 (SCI-Expanded, Scopus, TRDizin) Sustainable Development

41. The influence of obesity on biological agents treatment response in psoriatic arthritis: HUR-BIO real life results Obezitenin psöriyatik artritte biyolojik ajan tedavi yanıtı üzerindeki etkisi: HUR-BIO gerçek yaşam sonuçları

Farisoğulları B., Yardımcı G. K., Sarı A., Armağan B., BİLGİN E., BÖLEK E. Ç., et al.

Journal of Turkish Society For Rheumatology , vol.13, no.3, pp.107-115, 2021 (Scopus, TRDizin)

42. In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?

YAĞIZ B., COŞKUN B. N., PEHLİVAN Y., DALKILIÇ H. E., KİRAZ S., YAZISIZ V., et al.

RHEUMATOLOGY INTERNATIONAL , vol.41, no.11, pp.1915-1924, 2021 (SCI-Expanded, Scopus) Sustainable Development

43. Coronary (peri)-arteritis in patients with IgG4-related disease: A case series from the Central Anatolia Region of Turkey

Yardimci G. K., ARDALI DÜZGÜN S., BÖLEK E. Ç., KILIÇ L., CANPOLAT U., HAZIROLAN T., et al.

International Journal of Rheumatic Diseases , vol.24, no.8, pp.1004-1013, 2021 (SCI-Expanded, Scopus)

44. Biological and targeted-synthetic disease-modifying antirheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: Real-life TReasure prospective data

Kimyon G., KALYONCU U., KİRAZ S., Bes C., COŞKUN N. F., YAĞIZ B., et al.

Clinical and Experimental Rheumatology , vol.39, no.4, pp.852-858, 2021 (SCI-Expanded, Scopus)

45. Spinal and cerebral hematoma in systemic lupus erythematosus and antiphospholipid syndrome: Is drug interaction the culprit?

Duran E., BİLGİN E., BÖLEK E. Ç., Flrat O., Bulut E., KALYONCU U., et al.

Drug Metabolism and Personalized Therapy , vol.36, no.2, pp.169-172, 2021 (Scopus)

46. A case report of intracranial hypertension and aseptic meningitis: Anti-tumor necrosis factor associated or juvenile idiopathic arthritis related

KAYA AKCA Ü., Sökmen O., BÖLEK E. Ç., DEMİR S., KILIÇ L., Çevik I. Ü., et al.

Turkish Journal of Pediatrics , vol.63, no.3, pp.522-526, 2021 (SCI-Expanded, Scopus, TRDizin)

47. COVID-19 Among Patients With Inflammatory Rheumatic Diseases

Esatoglu S. N., Tascilar K., Babaoglu H., Bes C., Yurttas B., AKAR S., et al.

FRONTIERS IN IMMUNOLOGY , vol.12, 2021 (SCI-Expanded, Scopus) Sustainable Development

48. Direct oral anticoagulant for venous thrombosis in Behçet's syndrome

Vautier M., Gallien Y., Emmi G., Bettiol A., KARADAĞ Ö., BÖLEK E. Ç., et al.

Autoimmunity Reviews , vol.20, no.4, 2021 (SCI-Expanded, Scopus)

49. Is Takayasu’s arteritis more severe in children?

BÖLEK E. Ç., KAYA AKCA Ü., Sari A., SAĞ E., DEMİR S., KILIÇ L., et al.

Clinical and Experimental Rheumatology , vol.39, no.2, 2021 (SCI-Expanded, Scopus)

50. Iron deficiency and heart failure

Sener Y. Z., Oksul M., BÖLEK E. Ç.

ACTA CARDIOLOGICA , vol.76, no.1, pp.107, 2021 (SCI-Expanded, Scopus) Sustainable Development

51. Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience

BİLGİN E., Ceylan F., Duran E., Farisoğullari B., BÖLEK E. Ç., Yardimci G. K., et al.

Turkish Journal of Medical Sciences , vol.51, no.1, pp.297-308, 2021 (SCI-Expanded, Scopus, TRDizin)

52. Cerebral vasomotor reactivity in medically stabilized patients with takayasu’s arteritis Takayasu arteritinde stabil hastalık döneminde serebral vazomotor reaktivite

Pektezel M. Y., Rovshanov S., BÖLEK E. Ç., Khasiyev F., KARADAĞ Ö., ARSAVA E. M., et al.

Turk Noroloji Dergisi , vol.27, no.2, pp.123-127, 2021 (ESCI, Scopus, TRDizin)

53. Economic Burden of Osteoporotic Fractures: The Tip of the Iceberg?

BÖLEK H., BÖLEK E. Ç., DURUSU TANRIÖVER M.

AMERICAN JOURNAL OF MANAGED CARE , vol.26, no.12, 2020 (SCI-Expanded, SSCI, Scopus) Sustainable Development

54. Cancer incidence in Behçet’s disease

GÜVEN D. C., BÖLEK E. Ç., Altintop S. E., Celikten B., AKTAŞ B. Y., KİRAZ S., et al.

Irish Journal of Medical Science , vol.189, no.4, pp.1209-1214, 2020 (SCI-Expanded, Scopus)

55. Orthostatic hypotension among elderly patients in Italian internal medicine wards: an observational study—comment

Bolek H., BÖLEK E. Ç.

Internal and Emergency Medicine , vol.15, no.7, pp.1353-1354, 2020 (SCI-Expanded, Scopus)

56. Some concerns about poor outcome predictors for influenza virus infections

Bolek H., BÖLEK E. Ç.

European Journal of Internal Medicine , vol.78, pp.139-140, 2020 (SCI-Expanded, Scopus)

57. Predictors of drug retention and treatment response in axial spondyloarthritis patients treated with certolizumab: Real-life results from the HURBIO registry

BİLGİN E., Farisoğulları B., Armağan B., Sarı A., Yardımcı G. K., BÖLEK E. Ç., et al.

Clinical and Experimental Rheumatology , vol.38, no.4, pp.609-614, 2020 (SCI-Expanded, Scopus)

58. Management of Behcet's syndrome

KARADAĞ Ö., BÖLEK E. Ç.

Rheumatology (United Kingdom) , vol.59, 2020 (SCI-Expanded, Scopus)

59. Emergence of colistin and carbapenem-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii (CCR-Acb) complex in a neurological intensive care unit followed by successful control of the outbreak

METAN G., Zarakolu P., OTLU B., Tekin İ., Aytaç H., BÖLEK E. Ç., et al.

Journal of Infection and Public Health , vol.13, no.4, pp.564-570, 2020 (SCI-Expanded, Scopus)

60. Clinical features and disease course of neurological involvement in Behcet's disease: HUVAC experience

BÖLEK E. Ç., Sari A., KILIÇ L., KALYONCU U., Kurne A., Oguz K. K., et al.

Multiple Sclerosis and Related Disorders , vol.38, 2020 (SCI-Expanded, Scopus)

61. Some concerns from Turkey

BİLGİN E., Ozarli I., Klllç L., BÖLEK E. Ç., Yardlmcl G. K., KARADAĞ Ö.

Annals of the Rheumatic Diseases , vol.79, no.2, 2020 (SCI-Expanded, Scopus)

62. Indeterminate cell histiocytosis in a patient with systemic lupus erythematosus and antiphospholipid antibody syndrome: an unusual association

AKDOĞAN N., Demircan C., BÖLEK E. Ç., GÖKÖZ Ö., KARADUMAN A. A.

LUPUS , vol.29, no.1, pp.74-78, 2020 (SCI-Expanded, Scopus) Sustainable Development

63. The weekend effect in chronic hemodialysis patients, a single center experience

YILDIRIM T., Sener Y. Z., BÖLEK E. Ç., Yilmaz R., ARICI M., ALTUN B., et al.

Iranian Journal of Kidney Diseases , vol.14, no.3, pp.219-223, 2020 (SCI-Expanded, Scopus)

64. Do ANCA-associated vasculitides and IgG4-related disease really overlap or not?

Erden A., Bolek E. Ç., Yardimci K. G., KILIÇ L., Bilgen S. A., KARADAĞ Ö.

International Journal of Rheumatic Diseases , vol.22, no.10, pp.1926-1932, 2019 (SCI-Expanded, Scopus)

65. Successful Treatment of Amyloid A-Type Amyloidosis Due to Behcet Disease With Tocilizumab

Ilbay A., Erden A., Sari A., Armagan B., Aktas B. Y., Bolek E. Ç., et al.

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY , vol.25, no.4, 2019 (SCI-Expanded, Scopus) Sustainable Development

66. Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial

Oral F., BİLGİN E., BÖLEK E. Ç., Yardimci G. K., KILIÇ L.

RHEUMATOLOGY , vol.58, no.5, pp.925, 2019 (SCI-Expanded, Scopus) Sustainable Development

67. Interferon alpha might be an alternative therapeutic choice for refractory Neuro-Behcet's disease

BÖLEK E. Ç., Sari A., KILIÇ L., KARADAĞ Ö.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , vol.29, pp.153, 2019 (SCI-Expanded, Scopus) Sustainable Development

68. Thrombosis and Bleeding in Philadelphia Negative Myeloproliferative Neoplasia: Incidences and Risk Factors

OKAY M., MALKAN Ü. Y., Bolek E. C., Sayınalp N., BÜYÜKAŞIK Y., Haznedaroglu I. C.

Acta Medica , vol.50, no.2, pp.1-7, 2019 (TRDizin)

69. Rare occupational cause of nasal septum perforation: Nickel exposure

Bolek E. Ç., Erden A., Kulekci C., KALYONCU U., KARADAĞ Ö.

International journal of occupational medicine and environmental health , vol.30, no.6, pp.963-967, 2017 (SCI-Expanded, Scopus) Sustainable Development

70. The clinical features and outcomes of Turkish patients with IgG4-related disease: A single-center experience

KARADAĞ Ö., Erden A., AYHAN E. A., Bölek E. Ç., KALYONCU U., Armağan B., et al.

Turkish Journal of Medical Sciences , vol.47, no.5, pp.1307-1314, 2017 (SCI-Expanded, Scopus, TRDizin)

Papers Presented at Peer-Reviewed Scientific Conferences 82

1. POS1213 WHAT HAS THE FDAS BLACK BOX WARNINGS FOR JAKi CHANGED IN REAL LIFE HÜR-BIO REAL-LIFE EXPERIENCE

Bulat B., EKİCİ M., FIRLATAN B., Kart Bayram G. S., ÜNALDI E., AYAN G., et al.

European Congress of Rheumatology-EULAR 2025, Barselona, Spain, 11 June 2025, vol.84, pp.1276, (Summary Text)

2. ABS1074 BEHÇETS DISEASE BEYOND THE CRITERIA: INSIGHTS FROM A TERTIARY CENTER IN TURKEY

FIRLATAN B., Şahin Mavi E. A., Kart Bayram G. S., Bulat B., EKİCİ M., ÜNALDI E., et al.

European Congress of Rheumatology-EULAR 2025, Barselona, Spain, 11 - 14 June 2025, vol.84, pp.1577, (Summary Text)

3. REMARKING THE OSTEOPOROSIS IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS (AAV): DATA FROM EASTERN MEDITERRANEAN (TRVAS)

Demirci Yıldırım T., ERPEK KARAOVA E., ÖZDEMİR ULUSOY B., ÜNALDI E., SADİOĞLU ÇAĞDAŞ Ö., KARDAŞ R. C., et al.

European Congress of Rheumatology, Vienna, Austria, 12 - 15 June 2024, vol.83, (Summary Text) Sustainable Development

4. VENOUS THROMBOEMBOLISM IN ANCA-ASSOCIATED VASCULITIS MIGHT BE ASSOCIATED WITH DISEASE ACTIVITY: RESULTS OFTR-VaS COHORT

KOCAAYAN H., Durak Ediboğlu E., Demirci Yıldırım T., ÖZDEMİR B., Öğüt T. S., FIRLATAN B., et al.

Meeting of the European-Alliance-of-Associations-for-Rheumatology (EULAR), Vienna, Austria, 12 - 15 June 2024, vol.83, (Summary Text) Sustainable Development

5. REAL-LIFE DATA COMPARING THE LONG-TERM OUTCOME AND TREATMENT IN ADULT AND PEDIATRIC DADA2 PATIENTS: SINGLE CENTER EXPERIENCE OVER 10 YEARS

Ayan G., BAŞARAN H. Ö., BÖLEK E. Ç., Firlatan B., Bulat B., BATU AKAL E. D., et al.

Meeting of the European-Alliance-of-Associations-for-Rheumatology (EULAR), Vienna, Austria, 12 - 15 June 2024, vol.83, pp.1113-1114, (Summary Text)

6. ANCA ilişkili vaskülit hastalarında osteoporozu ne kadar tanıyoruz? Çok merkezli retrospektif analiz

DEMİRCİ YILDIRIM T., DURAN E., SADİOĞLU ÇAĞDAŞ Ö., KARDAŞ R. C., KIZILTEPE M., EKİCİ M., et al.

Ulusal Romatoloji Kongresi, Antalya, Turkey, 11 October 2023, (Full Text)

7. IgG4-Related Pachymeningitis: How Do I Recognize?

Arslan D., Yardimci G., BABAOĞLU B., BÖLEK E. Ç., KILIÇ L., Saglam A., et al.

9th Joint ECTRIMS-ACTRIMS meeting, Milan, Italy, 11 - 13 October 2023, vol.29, pp.656, (Summary Text)

8. PERFORMANCE OF 2022 ACR/EULAR GPA, EGPA AND MPA CLASSIFICATION CRITERIA IN TURKISH VASCULITIS STUDY GROUP PROSPECTIVE COHORT (TRVAS)

BÖLEK E. Ç., AYAN G., BİLGİN E., KÜÇÜK H., ERDEN A., ALİBAZ ÖNER F., et al.

EULAR (Avrupa Romatoloji Kongresi), Milan, Italy, 31 May 2023, (Full Text)

9. DEVELOPMENT OF THE TAKAYASU'S ARTERITIS INTEGRATED DISEASE ACTIVITY INDEX

Marvisi C., BÖLEK E. Ç., Ahlman M., Alessi H., Galli E., Ricordi C., et al.

European Congress of Rheumatology (EULAR), Milan, Italy, 31 May - 03 June 2023, vol.82, pp.641-642, (Summary Text)

10. PERFORMANCE OF 2022 ACR/EULAR GPA, EGPA AND MPA CLASSIFICATION CRITERIA IN TURKISH VASCULITIS STUDY GROUP PROSPECTIVE COHORT (TRVAS)

BÖLEK E. Ç., Ayan G., BİLGİN E., Ediboglu E. D., Duran E., Kardas C., et al.

European Congress of Rheumatology (EULAR), Milan, Italy, 31 May - 03 June 2023, vol.82, pp.1597-1598, (Summary Text) Sustainable Development

11. EULAR POINTS TO CONSIDER ON THE INITIATION OF TARGETED THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIDES AND A HISTORY OF CANCER

Sebbag E., Lauper K., Collada J. M., Aletaha D., Askling J., Benesova K., et al.

European Congress of Rheumatology (EULAR), Milan, Italy, 31 May - 03 June 2023, vol.82, pp.29, (Summary Text) Sustainable Development

12. AWARENESS OF EDUCATIONAL AND RESEARCH OFFERINGS OF EULAR AND EMEUNET AMONG YOUNG RHEUMATOLOGISTS WORKING IN TURKEY

Oztas M., Ayan G., BİLGİN E., BÖLEK E. Ç., Ilgen U.

European Congress of Rheumatology (EULAR), Milan, Italy, 31 May - 03 June 2023, vol.82, pp.2091-2092, (Summary Text)

13. SYSTEMATIC LITERATURE REVIEW INFORMING THE EULAR POINTS TO CONSIDER TASK FORCE ON THE INITIATION OF TARGETED THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIDES AND A HISTORY OF CANCER

Sebbag E., Molina Collada J., Lauper K., Aletaha D., Askling J., Benesova K., et al.

European Congress of Rheumatology (EULAR), Milan, Italy, 31 May - 03 June 2023, vol.82, pp.856, (Summary Text) Sustainable Development

14. EULAR RECOMMENDATIONS FOR THE USE OF IMAGING IN LARGE VESSEL VASCULITIS IN CLINICAL PRACTICE: 2023 UPDATE

Dejaco C., Ramiro S., Bond M., Bosch P., Ponte C., Mackie S., et al.

European Congress of Rheumatology (EULAR), Milan, Italy, 31 May - 03 June 2023, vol.82, pp.205, (Summary Text) Sustainable Development

15. HEMATOLOGICAL MALIGNANCIES AND ANTI-TNF IN INFLAMMATORY ARTHRITIS: THE REAL LIFE DATA FROM THE HUR-BIO REGISTRY

Duran E., Ozturk Z. O., BİLGİN E., BÖLEK E. Ç., Yardimci G. K., Farisogullari B., et al.

Annual European Congress of Rheumatology (EULAR), Copenhagen, Denmark, 1 - 04 June 2022, vol.81, pp.1064, (Summary Text)

16. THE EMERGING EULAR NETWORK (EMEUNET) PEER-REVIEW MENTORING PROGRAM: TEN YEARS OF INITIATIVE.

Verhoef L. M., Vivekanantham A., Berti A., BÖLEK E. Ç., Smeele H. T., Oztas M., et al.

Annual European Congress of Rheumatology (EULAR), Copenhagen, Denmark, 1 - 04 June 2022, vol.81, pp.202-203, (Summary Text) Sustainable Development

17. FREQUENCY OF DYSLIPIDEMIA AND COMPLIANCE WITH THE TREATMENT IN PSA PATIENTS USING BDMARDS

Gezerer N. E., Ayan G., BİLGİN E., Yardimci G. K., BÖLEK E. Ç., Farisogullari B., et al.

Annual European Congress of Rheumatology (EULAR), Copenhagen, Denmark, 1 - 04 June 2022, vol.81, pp.869, (Summary Text)

18. IS PSORIATIC ARTHRITIS REALLY SERONEGATIVE?

Ayan G., Gezerer N. E., BİLGİN E., Yardimci G. K., BÖLEK E. Ç., Farisogullari B., et al.

Annual European Congress of Rheumatology (EULAR), Copenhagen, Denmark, 1 - 04 June 2022, vol.81, pp.1598-1599, (Summary Text) Sustainable Development

19. PREDICTORS OF SUSTAINED REMISSION IN PEOPLE WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIOLOGIC DRUGS

Farisogullari B., Yardimci G. K., BİLGİN E., BÖLEK E. Ç., Duran E., Ayan G., et al.

Annual European Congress of Rheumatology (EULAR), Copenhagen, Denmark, 1 - 04 June 2022, vol.81, pp.776, (Summary Text)

20. PREDICTORS OF DEVELOPMENT OF ADVANCED SPINAL ANKYLOSIS/BAMBOO SPINE IN AXIAL SPONDYLOARTHRITIS: RESULTS FROM REAL-LIFE DATA

Farisogullari B., Yardimci G. K., BİLGİN E., BÖLEK E. Ç., Duran E., Ayan G., et al.

Annual European Congress of Rheumatology (EULAR), Copenhagen, Denmark, 1 - 04 June 2022, vol.81, pp.803-804, (Summary Text) Sustainable Development

21. CARDIOVASCULAR EVENT, VENOUS THROMBOEMBOLIZM, AND INFECTION RISK WITH TOFACITINIB IN RHEUMATOID ARTHRITIS PATIENTS AGED ≥ 60 YEARS

Duran E., Unaldi E., BİLGİN E., BÖLEK E. Ç., Yardimci G. K., Farisogullari B., et al.

Annual European Congress of Rheumatology (EULAR), Copenhagen, Denmark, 1 - 04 June 2022, vol.81, pp.1336, (Summary Text) Sustainable Development

22. BDMARD CHOICES FOR INFLAMMATORY ARTHRITIS WITH CHRONIC KIDNEY DISEASE; HUR-BIO REAL-LIFE REGISTRY

Uzun G. S., Taghiyeva A., YALÇIN ÇAKIR F., Moral K., BİLGİN E., Yardimci G. K., et al.

Annual European Congress of Rheumatology (EULAR), Copenhagen, Denmark, 1 - 04 June 2022, vol.81, pp.1303, (Summary Text) Sustainable Development

23. THE FREQUENCY, PREVALENCE OF CORONARY ARTERY DISEASE AND PRE-MATURE CAD IN PSA AND RA PATIENTS

Ayan G., Uzun G. S., Tatar O. D., Gezerer N. E., BİLGİN E., Yardimci G. K., et al.

Annual European Congress of Rheumatology (EULAR), Copenhagen, Denmark, 1 - 04 June 2022, vol.81, pp.1263-1264, (Summary Text) Sustainable Development

24. DYSLIPIDEMIA TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS USING BDMARDS IS BETTER THAN PSA, BUT THERE IS STILL A WAY TO GO

Uzun G. S., Tatar O. D., Gezerer N. E., BİLGİN E., Yardimci G. K., BÖLEK E. Ç., et al.

Annual European Congress of Rheumatology (EULAR), Copenhagen, Denmark, 1 - 04 June 2022, vol.81, pp.1264-1265, (Summary Text)

25. ASSOCIATION OF DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER AND AXIAL SPONDYLOARTHRITIS WITH THE M694V MUTATION

Kiraci M., BİLGİN E., Duran E., Farisogullari B., BÖLEK E. Ç., Yardimci G. K., et al.

Annual European Congress of Rheumatology (EULAR), Copenhagen, Denmark, 1 - 04 June 2022, vol.81, pp.797, (Summary Text) Sustainable Development

26. OSTEOPOROSIS IN PATIENTS WITH SPONDYLOARTHRITIS: DO WE NEED TO DO MORE?

Ozsoy Z., Moral K., YEŞİL F., BİLGİN E., BÖLEK E. Ç., Yardimci G. K., et al.

Annual European Congress of Rheumatology (EULAR), Copenhagen, Denmark, 1 - 04 June 2022, vol.81, pp.1547, (Summary Text)

27. IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING BDMARDS, THE CHARLSON COMORBIDITY INDEX IS MORE PRONOUNCED THAN PSORIATIC ARTHRITIS

Uzun G. S., Tatar O. D., Gezerer N. E., BİLGİN E., Yardimci G. K., BÖLEK E. Ç., et al.

Annual European Congress of Rheumatology (EULAR), Copenhagen, Denmark, 1 - 04 June 2022, vol.81, pp.1265, (Summary Text)

28. THE RELATIONSHIP BETWEEN CHANGES IN PSORIATIC ARTHRITIS DISEASE ACTIVITY AND COMORBIDITIES IN PATIENTS TREATED WITH BDMARDS

Ayan G., Gezerer N. E., BİLGİN E., Yardimci G. K., BÖLEK E. Ç., Farisogullari B., et al.

Annual European Congress of Rheumatology (EULAR), Copenhagen, Denmark, 1 - 04 June 2022, vol.81, pp.870, (Summary Text) Sustainable Development

29. A Prospective Observational Cohort Study and Systematic Review of 40 Patients with Mouth and Genital Ulcers with Inflamed Cartilage (MAGIC) Syndrome

Luo Y., BÖLEK E. Ç., Quinn K., Wells K., Rose E., Rominger E., et al.

ACR Convergence Conference, ELECTR NETWORK, 5 - 09 November 2021, vol.73, pp.3921-3922, (Summary Text)

30. ¹⁸F-Fluorodeoxyglucose PET/MRI as an Alternative Hybrid Imaging Modality: Comparative Study in a Prospective, Longitudinal Cohort of Patients with Large-Vessel Vasculitis

BÖLEK E. Ç., Quinn K., Alessi H., Novakovich E., Ahlman M. A., Grayson P.

ACR Convergence Conference, ELECTR NETWORK, 5 - 09 November 2021, vol.73, pp.3898-3900, (Summary Text)

31. Real-life Data for the Use of Anti-TNF Treatment in DADA2

KARADAĞ Ö., Ayan G., BAŞARAN H. Ö., BÖLEK E. Ç., KILIÇ L., BİLGİNER Y., et al.

ACR Convergence Conference, ELECTR NETWORK, 5 - 09 November 2021, vol.73, pp.3935-3939, (Summary Text)

32. Using 18F-fluorodeoxyglucose Positron Emission Tomography to Standardize Clinical Trial Recruitment in Takayasu's Arteritis

Quinn K., Alessi H., Rose E., Ahlman M. A., Redmond C., Luo Y., et al.

ACR Convergence Conference, ELECTR NETWORK, 5 - 09 November 2021, vol.73, pp.3918-3919, (Summary Text)

33. Comparison of Demographic, Clinic and Radiological Features of Axial Spondyloarthritis Patients with and Without Accompanying Familial Mediterranean Fever

Kiraci M., BİLGİN E., Duran E., Farisogullari B., BÖLEK E. Ç., Yardimci G. K., et al.

ACR Convergence Conference, ELECTR NETWORK, 5 - 09 November 2021, vol.73, pp.771-773, (Summary Text)

34. Cancer in Patients with ANCA-associated Vasculitis: Which Came First, the Chicken or the Egg?

Ediboglu E., Kardas R. C., BÖLEK E. Ç., Yildirim R., Guven D., Kilickap S., et al.

ACR Convergence Conference, ELECTR NETWORK, 5 - 09 November 2021, vol.73, pp.867-870, (Summary Text)

35. Validation of Angiographic Patterns of Disease in a Turkish Cohort of Patients with Takayasu's Arteritis

Gribbons K. B., Kaymaz--Tahra S., ALİBAZ F., BÖLEK E. Ç., KARADAĞ Ö., İNCE B., et al.

ACR Convergence Conference, ELECTR NETWORK, 5 - 09 November 2021, vol.73, pp.3941-3943, (Summary Text)

36. RENAL BIOPSY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: IS IT ONLY LUPUS NEPHRITIS?

Duran E., YILDIRIM T., KALYONCU U., Taghiyeva A., BİLGİN E., Saglam E. A., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 2 - 05 June 2021, vol.80, pp.1198-1199, (Summary Text) Sustainable Development

37. FERTILITY AND PREGNANCY OUTCOMES IN TAKAYASU'S ARTERITIS

Taghiyeva A., KILIÇ L., ÇAĞAN M., BÖLEK E. Ç., Yardimci G. K., KARADAĞ Ö., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 2 - 05 June 2021, vol.80, pp.659-660, (Summary Text)

38. ANXIETY IN PSORIATIC ARTHRITIS PATIENTS: RESULTS FROM THE HUR-BIO BIOLOGIC REGISTRY

Ayan G., Farisogullari B., BİLGİN E., BÖLEK E. Ç., Yardimci G. K., Duran E., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 2 - 05 June 2021, vol.80, pp.814, (Summary Text) Sustainable Development

39. TRENDS IN THE CHOICE OF FIRST BIOLOGIC AND TARGETED SYNTHETIC DMARD IN RHEUMATOID ARTHRITIS PATIENTS: 20-YEARS JOURNEY OF HURBIO REAL-LIFE REGISTRY

ERTENLİ A. İ., KALYONCU U., KARADAĞ Ö., KILIÇ L., AKDOĞAN A., Dogan I., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 2 - 05 June 2021, vol.80, pp.1124, (Summary Text) Sustainable Development

40. CHANGES IN THE PRESCRIPTION PATTERNS OF THE SECOND-LINE BIOLOGIC AND TARGETED SYNTHETIC DMARD IN RHEUMATOID ARTHRITIS PATIENTS: 20-YEARS JOURNEY OF HUR-BIO REAL-LIFE REGISTRY

KİRAZ S., KALYONCU U., KARADAĞ Ö., KILIÇ L., AKDOĞAN A., Dogan I., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 2 - 05 June 2021, vol.80, pp.1124-1125, (Summary Text)

41. PREDICTORS OF END STAGE RENAL DISEASE IN THE RENAL BIOPSY PROVEN LUPUS NEPHRITIS

Duran E., YILDIRIM T., KALYONCU U., Taghiyeva A., AYHAN E. A., ÜNER M., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 2 - 05 June 2021, vol.80, pp.648-649, (Summary Text)

42. OBESITY RATES AND BMI ARE SIMILAR IN AGE AND SEX MATCHED RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND SPONDYLOARTHRITIS PATIENTS

Yardimci G. K., Farisogullari B., BÖLEK E. Ç., BİLGİN E., Duran E., Ayan G., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 2 - 05 June 2021, vol.80, pp.518-519, (Summary Text) Sustainable Development

43. PRESCRIPTION PATTERNS OF THE SECOND BIOLOGIC DMARD IN PSORIATIC ARTHRITIS THROUGH THE LAST DECADE: HURBIO-PsA REAL LIFE EXPERIENCE

KALYONCU U., KARADAĞ Ö., KILIÇ L., AKDOĞAN A., Dogan I., Bilgen S. A., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 2 - 05 June 2021, vol.80, pp.1299, (Summary Text)

44. COMPARISON OF DEMOGRAPHIC AND CLINICAL FEATURES OF FAMILIAL MEDITERRANEAN FEVER PATIENTS AND PATIENTS WITH AXIAL SPONDYLOARTHRITIS ACCOMPANYING FAMILIAL MEDITERRANEAN FEVER

Kiraci M., BİLGİN E., Duran E., Farisogullari B., BÖLEK E. Ç., Yardimci G. K., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 2 - 05 June 2021, vol.80, pp.971, (Summary Text)

45. RETENTION RATE AND TREATMENT RESPONSE OF BIOLOGICAL AGENTS IN ADVANCED SPINAL ANKYLOSIS AND BAMBOO SPINE: THE REAL LIFE DATA FROM THE HURBIO REGISTRY

Farisogullari B., Yardimci G. K., BÖLEK E. Ç., BİLGİN E., Duran E., Ayan G., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 2 - 05 June 2021, vol.80, pp.728-729, (Summary Text) Sustainable Development

46. DURATION OF STARTING bDMARDs ARE ALMOST 3 TIMES LONGER IN RA PATIENTS THAN PsA PATIENTS: HUR-BIO REAL LIFE RESULTS

Yardimci G. K., Farisogullari B., BÖLEK E. Ç., BİLGİN E., Duran E., Ayan G., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 2 - 05 June 2021, vol.80, pp.554-555, (Summary Text) Sustainable Development

47. BOTH SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS PATIENTS HAVE STRONG FAMILY HISTORIES

Yardimci G. K., Farisogullari B., BÖLEK E. Ç., BİLGİN E., Duran E., Ayan G., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 2 - 05 June 2021, vol.80, pp.770-771, (Summary Text) Sustainable Development

48. CONVENTIONAL SYNTHETIC DMARDS IN PSORIATIC ARTHRITIS - CHANGING PRACTICE IN BIOLOGIC ERA: REAL-LIFE RESULTS FROM HURBIO-PSA REGISTRY

BİLGİN E., Duran E., BÖLEK E. Ç., Farisogullari B., Yardimci G. K., KILIÇ L., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.1663, (Summary Text)

49. REAL-LIFE EXPERIENCE FOR SECUKINUMAB IN PSORIATIC ARTHRITIS FROM HURBIO-PSA DATABASE

BÖLEK E. Ç., BİLGİN E., Yardimci G. K., Farisogullari B., Duran E., Armagan B., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.1665-1666, (Summary Text)

50. THE INFLUENCE OF OBESITY ON BIOLOGICAL DMARD TREATMENT RESPONSE IN PSORIATIC ARTHRITIS: HUR-BIO REAL LIFE RESULTS

Farisogullari B., Yardimci G. K., BÖLEK E. Ç., BİLGİN E., Duran E., Ayan G., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.1675-1676, (Summary Text) Sustainable Development

51. FACTORS RELATED TO RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS-RELATED INTERSTITIAL LUNG DISEASE

KALYONCU U., Ekici M., BİLGİN E., Sari A., Baytar Y., BÖLEK E. Ç., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.1394, (Summary Text) Sustainable Development

52. CONCOMITANT PSORIATIC ARTHRITIS AND INFLAMMATORY BOWEL DISEASE IN THE PSA BIOLOGICAL REGISTRY: HUR-BIO REAL LIFE RESULTS

Yardimci G. K., Farisogullari B., Armagan B., BİLGİN E., BÖLEK E. Ç., Duran E., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.1174-1175, (Summary Text)

53. INCIDENCE RATE OF HERPES ZOSTER IN RHEUMATOID ARTHRITIS PATIENTS UNDER TOFACITINIB: REAL-LIFE DATA FROM TURKEY - HURBIO REGISTRY

BİLGİN E., Ceylan F., Duran E., BÖLEK E. Ç., Farisogullari B., Yardimci G. K., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.636, (Summary Text) Sustainable Development

54. CANCER INCIDENCE AND FEATURES IN ADULT VASCULITIS PATIENTS

Kardas R. C., BÖLEK E. Ç., AKTAŞ B. Y., Kilickap S., KARADAĞ Ö.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.682-683, (Summary Text) Sustainable Development

55. SUBPHENOTYPES IN POLYARTERITIS NODOSA (PAN): TARGET ORGAN ASSOCIATIONS OF A WORLDWIDE COLLABORATION STUDY

KARADAĞ Ö., BÖLEK E. Ç., Furuta S., Emmi G., Hocevar A., Hinojosa-Azaola A., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.1060-1061, (Summary Text)

56. LOCALISATION OF RHEUMATOID LUNG NODULES IN PATIENTS WITH RHEUMATOID ARTHRITIS-RELATED INTERSTITIAL LUNG DISEASE: RIGHT OR LEFT?

BİLGİN E., Ekici M., Baytar Y., Duran E., DURHAN G., BÖLEK E. Ç., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.277, (Summary Text) Sustainable Development

57. CONCOMITANT USE OF BIOLOGIC DMARDS WITH CSDMARDS INCREASES DRUG RETENTION RATE AND IMPROVES TREATMENT RESPONSE IN THE PSORIATIC ARTHRITIS. HUR-BIO REAL LIFE RESULTS

Duran E., BİLGİN E., BÖLEK E. Ç., Yardimci G. K., Farisogullari B., KILIÇ L., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.757, (Summary Text)

58. INFLAMMATORY ORBITAL DISEASES: THE EXPERIENCE OF A TERTIARY RHEUMATOLOGY CENTRE

Aksun M. S., Sahin T. K., BÖLEK E. Ç., KILIÇ L., BULUT E. G., Oguz K. K., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.1806-1807, (Summary Text)

59. SECUKINUMAB IS FREQUENTLY PREFERRED IN MULTI ANTI-TNF RESISTANCE SPONDYLOARTHRITIS PATIENTS: HUR-BIO REAL LIFE RESULTS

Armagan B., KILIÇ L., Yardimci G. K., BİLGİN E., Farisogullari B., BÖLEK E. Ç., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.419-420, (Summary Text)

60. EFFICACY, RETENTION RATE AND PREDICTORS OF TOFACITINIB EFFICACY AND RETENTION IN RHEUMATOID ARTHRITIS PATIENTS: HUR-BIO REAL-LIFE EXPERIENCE

BİLGİN E., Ceylan F., BÖLEK E. Ç., Duran E., Farisogullari B., Yardimci G. K., et al.

Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 03 June 2020, vol.79, pp.1460, (Summary Text)

61. Cancer incidence in Behcet's Disease.

Guven D. C., BÖLEK E. Ç., Altintop S. E., Celikten B., Aktas B. Y., Kiraz S., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 May 2020, vol.38, (Summary Text)